GI Hepatobiliary

Hepatocellular Carcinoma

Localized

- No Prior Therapy
  - 1st Line
    - No Trials Currently Available
      - IRB# 2377: A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

Prior Therapy

- 2nd line
  - No Trials Currently Available

Cholangiocarcinoma

- 1st Line
- 1st or 2nd Line

IRB# 16255: INCB 54828-202: A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

IRB# 16133: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

IRB# 16033

http://www.ohsu.edu/research/rda/so/knight.php